Roche signs deal with Skyhawk over molecules that modulate RNA splicing
pharmafile | July 17, 2019 | News story | Research and Development | Genentech, Roche, Skyhawk, drug development, rna splicing
Roche’s Genentech unit has signed a deal with Massachusetts-based firm Skyhawk Therapeutics to develop and commercialise small molecules that modulate RNA splicing.
The deal will see Skyhawk use its drug discovery platform SkyStar to discover and develop treatments for oncology and neurological disease targets.
Genentech will then have exclusive rights to develop and commercialise potential therapeutics while paying Skyhawk upfront payments and royalties.
“Genentech has long been a leader in advancing drug discovery for oncology and neurodegenerative disorders,” said Bill Haney, co-founder and chief executive officer of Skyhawk.
“We look forward to continuing to demonstrate the utility of SkyStar to discover novel RNA splicing modifiers directed to targets important in the treatment of neurodegenerative diseases and cancer. We share Genentech’s passion for transforming patients’ lives and look forward to working with the Genentech team to potentially expand the treatment options available to patients.”
Dr James Sabry, global head of Pharma Partnering, Roche, added: “Modulation of RNA splicing represents a novel approach for difficult-to-treat diseases. Skyhawk has developed unique expertise in splicing biology, and we are excited to work with their team to discover potential new medicines for patients with cancer and neurodegenerative diseases.”
Louis Goss
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …